KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Intangibles (2016 - 2026)

TherapeuticsMD filings provide 17 years of Intangibles readings, the most recent being $6.2 million for Q1 2026.

  • On a quarterly basis, Intangibles rose 49.44% to $6.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.2 million, a 49.44% increase, with the full-year FY2025 number at $6.2 million, down 3.06% from a year prior.
  • Intangibles hit $6.2 million in Q1 2026 for TherapeuticsMD, roughly flat from $6.2 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $48.4 million in Q3 2022 to a low of $3.9 million in Q3 2025.
  • Median Intangibles over the past 5 years was $6.4 million (2024), compared with a mean of $12.9 million.
  • Biggest five-year swings in Intangibles: crashed 86.26% in 2023 and later skyrocketed 49.44% in 2026.
  • TherapeuticsMD's Intangibles stood at $6.9 million in 2022, then fell by 12.17% to $6.1 million in 2023, then increased by 4.61% to $6.4 million in 2024, then fell by 3.06% to $6.2 million in 2025, then changed by 0.0% to $6.2 million in 2026.
  • The last three reported values for Intangibles were $6.2 million (Q1 2026), $6.2 million (Q4 2025), and $3.9 million (Q3 2025) per Business Quant data.